Canada Bio-Mfg Facility & COVID-19 reserved vaccines

Canada signs agreements with Pfizer, Novavax, J&J, & Moderna

  • Pfizer, will supply a minimum of 20 million doses of its mRNA-based vaccine candidate, BNT162. Options for obtaining additional doses are under discussion.
  • Johnson & Johnson, will supply up to 38 million doses of its vaccine candidate Ad26.COV2.S.
  • Novavax, will supply up to 76 million doses of its vaccine candidate NVX-CoV2373.
  • Moderna, will supply up to 56 million doses of its vaccine candidate mRNA-1273.

Minister: “Aggressive approach in procuring a portfolio of the most promising vaccine candidates”

According to the Minister of Public Services and Procurement, Anita Anand, “As we continue our work to purchase the supplies and equipment that are necessary to combat the COVID-19 pandemic, we remain equally focused on planning for the future, including securing potential vaccines for Canadians. We are taking an aggressive approach in procuring a portfolio of the most promising vaccine candidates in order to ensure that Canadians will have access to them as quickly as possible once they have been approved.”

Canada already has a $1 billion fund through the ‘Plan to Mobilize Science to fight COVID-19′ to develop a vaccine and treatments, as well as to track the virus. Of this fund, $600 million supports private sector work to develop a vaccine. See Canadian projects in chart below.

None of these vaccines have been approved as yet. They are in various stages of preliminary testing. See chart below.

According to a Canadian government statement, “Health Canada will review the evidence of safety, efficacy, and manufacturing quality for each vaccine to determine whether individual vaccines will be approved for use in Canada, before they are used to vaccinate Canadians.”

Read if you wish the standards testing should meet: COVID-19 vaccine trials should seek worthwhile efficacy Pub: 27 August 2020


Two Million Doses per Month Facility in Montreal at NRC

Canada will rapidly establish a new $126 million bio-manufacturing facility at the Human Health Therapeutics Research Centre (at NRC)  in Montréal.

Through a public-private partnership, the new facility according to the Canadian government “will enable the National Research Council of Canada (NRC) to increase vaccine manufacturing to up to two million doses per month by next year”.

“Canada’s Current Status in the Fight Against COVID-19: Cases leveling, CFR Remains High,” says Civil Society biostatistician.

Canada maintains control over COVID-19 although Infection fatality rate is high

Click image to enlarge. Canada maintains control over COVID-19 although Case Fatality Rate (CFR) is high and Infection Fatality Rate (IFR) may be very high. Source: Fred Harris, biostatistician, Civil Society COVID-19 Tracking Group Art/Cropping/Enhancement: Rosa Yamamoto FPMag

June 29, 2022

Population: 38,745,871 adjusted for estimated real COVID-19 deaths

Reported:3,948,18641,896 1.06% CFR3,852,87953,411
Estimate:21,833,46954,464 *0.25% IFR21,306,421295,363

*Inferred IFR is an estimate only. The actual COVID-19 IFR may not be accurately calculated for the entire human race until long after the pandemic has ended.

Canada ProvincesDeathsCFR%CasesCuredActive
COVID-19 Totals:41,8961.063,948,1863,852,87953,411
* Quebec15,5721.431,087,0251,061,41710,036
First Nations7400.67110,221108,0131,468
Nova Scotia4210.42101,34799,4061,520
* PEI450.1140,80639,6931,068
* NWT220.1812,13512,09419
Sub Totals41,8961.063,948,1863,852,87953,411

Recoveries are estimated using a Canadian-specific algorithm. Canadian COVID-19 Data is weekly by the country. Some data CSPAC obtains from Public Health Units is updated daily.

* Quebec, * Northwest Territories, * Prince Edward Island data is current daily.
Note: Last available First Nations data is shown when provided by the federal government of Canada.

Below: Extensive Estimates using data from multiple sources.

Beta experimental estimates for Canada. Reported + unreported mild + asymptomatic COVID-19 infections.

The total actual number of infections in Canada including all the untested, unreported, asymptomatic infections is likely greater than 21,833,469 (56.35% of the population) including mild and asymptomatic cases. That would mean the estimated inferred average Infection Fatality Rate:
(IFR) is likely around 0.25%

Canadian COVID-19 deaths to 2022-06-29 are estimated to be 54,584 Using estimated IFR of 0.25% which is far below global average IFR.

54,584 (0.25% IFR) is the CSPaC estimated number of Canadian COVID-19 deaths (based on the inferred IFR) including those deaths unreported as COVID-19). The IHME estimates excess deaths in Canada to reach much higher than CSPaC estimates.

See The Lancet estimate of excess mortality from COVID-19 (Download PDF) in 191 countries/territories and 252 subnational units of select countries, from 1 January 2 0 2 0, to 31 December 2 0 2 1.

54464 Is the CSPaC estimated number of Canadian COVID-19 deaths based on a modified universal algorithm which factors more sophisticated public health infrastructure and also fewer available urgent care beds and facilities which is a problem in much of Canada in an emergency measures context.

The closeness of the two numbers derived from unique data and methods suggests their high probability. The blended data of three projections from three different biostatistician labs also confirms the estimates +/- .01%.

It is safe to say that Canadians have endured the grief of losing 54464 family members. Every number has a face. May their memory be forever a blessing to their families and friends.

Canada's advanced public health standards.

Canada and the USA both have a significantly lower than global average Infection Fatality Rate. (influenza has an IFR of .1% or 6 per 100k (2019)).

Ontario, Canada Reports

Ontario Regional Public Health Units (PHU) - Reported by Ontario Province.

These reports from the Ontario Provincial government differ significantly (much lower) from the data reported by individual Public Health Units (PHU). CSPaC includes links to each PHU to allow readers of this report to check the latest data from their public health unit.

Health UnitCasesDeathsCFRRecoveriesActive
Algoma District8,581570.7%8,44579
Brant County11,873830.7%11,74149
Durham Region63,0714960.8%62,295280
Eastern Ontario16,0972181.4%15,82158
Grey Bruce8,873690.8%8,76737
Haliburton Kawartha Pine Ridge9,4981111.2%9,33255
Halton Region49,6273270.7%49,057243
Hastings & Prince Edward Counties10,388630.6%10,25471
Huron Perth7,4281111.5%7,29126
Kingston Frontenac Lennox & Addington17,560600.3%17,298202
Lambton County11,9031461.2%11,72334
Leeds Grenville And Lanark District9,5671061.1%9,357104
Niagara Region41,5845481.3%40,829207
North Bay Parry Sound District6,132440.7%6,03751
Oxford Elgin-St.Thomas13,9911691.2%13,76755
Peel Region186,6161,3560.7%184,468792
Peterborough County-City7,607801.1%7,48146
Renfrew County And District4,827501.0%4,74433
Simcoe Muskoka District46,6344380.9%45,927269
Sudbury And District15,5221501.0%15,240132
Thunder Bay District12,907960.7%12,640171
Waterloo Region46,7564210.9%46,139196
Windsor-Essex County44,2246321.4%43,433159
York Region112,8551,0420.9%111,193620
Last Updated: 2022-06-29 Time 05:46:25 GMT. Source: CSPaC

Justin Trudeau, Prime Minister of Canada said Monday that, “As we continue to work together to limit the impact of the COVID-19 pandemic on the health of Canadians, as well as its social and economic effects, we must also maximize our chances of defeating the virus. To do this, we need to invest in the development of several promising vaccines and ensure that we can manufacture and distribute the vaccine to as many Canadians as possible, as quickly as possible. That is how we will move forward on a sustainable path to a full recovery.”

Watch Patty Hajdu, Minister of Health.



Chart: SARS2-CoV-2 vaccine candidates in Phase 1-3 plus significant candidates in pre-clinical R&D


Candidate Sponsor Trial Phase Institution
bacTRL-Spike Symvivo Pre-clinical Symvivo Corporation
PittCoVacc UPMC/University
of Pittsburgh School of Medicine
Pre-clinical University of Pittsburgh
V591 University of Pittsburgh’s Center
for Vaccine Research
Pre-clinical University of PittsburghThemis
Ii-Key peptide COVID-19 vaccine Generex Biotechnology Pre-clinical Generex
Recombinant vaccine Vaxart Pre-clinical Vaxart
LineaDNA Takis Biotech Pre-clinical Takis Biotech
AdCOVID Altimmune Pre-clinical University of Alabama at
T-COVIDTM Altimmune Pre-clinical
Protein subunit vaccine University of Saskatchewan Vaccine
and Infectious Disease Organization-International Vaccine Centre
Pre-clinical University of Saskatchewan Vaccine
and Infectious Disease Organization-International Vaccine Centre
Adenovirus-based vaccine ImmunityBioNantKwest Pre-clinical
AAVCOVID Massachusetts Eye and Ear; Massachusetts General Hospital;
University of Pennsylvania
Recombinant vaccine SanofiTranslate
HaloVax Voltron Therapeutics, Inc.; Hoth Therapeutics, Inc. Pre-clinical MGH Vaccine and
Immunotherapy Center
mRNA-based vaccine Chulalongkorn University’s Center
of Excellence in Vaccine Research and Development
HDT-301 University of WashingtonNational
Institutes of Health Rocky Mountain Laboratories
Bio Corp
gp96-based vaccine Heat Biologics Pre-clinical University of Miami Miller School
of Medicine
ChAd-SARS-CoV-2-S Washington University School
of Medicine in St. Louis
Pre-clinical Washington University School
of Medicine in St. Louis
Inactivated vaccine Wuhan
Institute of Biological Products
National Pharmaceutical Group (Sinopharm)
Phase 3 Henan Provincial Center for Disease Control and Prevention
CoronaVac Sinovac Phase 3 Sinovac Research and
Development Co., Ltd.
mRNA-1273 Moderna Phase 3
Kaiser Permanente Washington Health Research Institute
Ad5-nCoV CanSino Biologics Phase 3 Tongji Hospital; Wuhan,
NVX-CoV2373 Novavax Phase 2b Novavax
Bacillus Calmette-Guerin (BCG) live-attenuated vaccine University of Melbourne and
Murdoch Children’s Research Institute
University Medical Center
Lab at Massachusetts General Hospital
Phase 2/3 University of Melbourne and
Murdoch Children’s Research Institute
University Medical Center
Lab at Massachusetts General Hospital
AZD1222/Covishield The University of OxfordAstraZenecaIQVIA;
Serum Institute of India
Phase 2/3 The University of Oxfordthe
Jenner Institute
BNT162 PfizerBioNTech Phase 2/3 Multiple study sites in Europe and North America
Adjuvant recombinant vaccine candidate Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of
the Chinese Academy of Sciences
Phase 2
ZyCoV-D Zydus Cadila Phase 2 Zydus Cadila
Covaxin Bharat BiotechNational
Institute of Virology
Phase 2
BBIBP-CorV Beijing Institute of Biological Products; China
National Pharmaceutical Group (Sinopharm)
Phase 1/2 Henan Provincial Center for Disease Control and Prevention
GRAd-COV2 Genexine Phase 1/2
Sputnik V Gamaleya Research Institute, Acellena Contract Drug Research and
Phase 1/2 Various
Self-amplifying RNA vaccine Imperial College London Phase 1/2
Imperial College London
LUNAR-COV19 Arcturus Therapeutics and Duke-NUS
Medical School
Phase 1/2 Duke-NUS Medical School,
INO-4800 Inovio Pharmaceuticals Phase 1/2 Center for Pharmaceutical Research,
Kansas City. Mo.; University
of Pennsylvania
, Philadelphia
Ad26.COV2-S Johnson & Johnson Phase 1/2 Johnson & Johnson
mRNA-based vaccine CureVac Phase 1 CureVac
SCB-2019 GlaxoSmithKlineSanofiClover
Dynavax and
Xiamen Innovax
Phase 1 Linear Clinical Research
COVAX-19 Vaxine Pty Ltd. Phase 1 Royal Adelaide Hospital
Plant-based adjutant COVID-19 vaccine candidate MedicagoGSKDynavax Phase 1 Medicago
Molecular clamp vaccine CSLThe
University of Queensland
Phase 1
V590 MerckIAVI Phase 1
GRAd-COV2 ReiTheraLeukocareUnivercells Phase 1
Lazzaro Spallanzani National Institute for Infectious Diseases
AdimrSC-2f Adimmune Phase 1 Adimmune
mRNA lipid nanoparticle (mRNA-LNP) vaccine CanSino BiologicsPrecision
Early research


Chart Data Source: Regulatory Affairs Professionals Society.


Read also:

Civil Society aims at children to demystify SARS2 vaccines

“Do Minions Catch The Virus?” asked the nurse at a remote clinic while speaking to some children. “Not if they do these simple things,” she went on. Hey kids. Funny Minions, silly Gru, some moms, doctors and nurses explain social